Water-soluble coenzyme Q10 formulation in presbycusis [age-associated hearing loss]: Long-term effects – Source: Acta Otolaryngologica, Dec 16, 2010

1 Star2 Stars3 Stars4 Stars5 Stars (10 votes, average: 3.30 out of 5)
Loading...

[Note: the ubiquinol form of the antioxidant nutrient CoQ10 is water soluble, while the ubiquinone form is lipid (fat) soluble. The body needs both, and normally converts ubiquinone to ubiquinol as needed, but aging, chronic illness, and the use of statin drugs may deplete its ability to accomplish this conversion. Further, water soluble ubiquinol CoQ10 is up to 8 times more absorbable than ubiquinone. Pure tone audiometry is the key hearing test used to identify hearing sensitivity.]

Conclusion: These findings provide the basis for understanding the duration of the effect after the last use of the drug and encourage a larger clinical trial to collect additional evidence on the effect of coenzyme Q10 (CoQ10) in preventing the development of hearing loss in subjects with presbycusis. [Age-related reduction of hearing acuity.]

Objectives: The aim of this study was to evaluate the long-term effects of a water-soluble formulation of CoQ10 (Q-TER) in subjects with presbycusis.

Methods: Sixty patients with presbycusis were included and divided at random into three numerically equal groups.

For 30 days, group A underwent therapy with Q-TER, group B underwent therapy with vitamin E, and group C received placebo.

Before, at the end, and 6 months after the end of the treatment, all patients underwent evaluation of pure tone audiometry, transient evoked otoacoustic emissions and otoacoustic products of distortion, auditory brainstem response, and speech audiometry.

Results: Compared with group B [vitamin E], at the end of the treatment in group A [CoQ10] the pure tone audiometry showed a significant (p < 0.05) improvement of the audiometric thresholds at 1000, 2000, 4000, and 8000 Hz.

This improvement was confirmed by the speech audiometry and last check. We found no significant differences in the other parameters and in group C [placebo group].

Source: Acta Otolaryngologica, Dec 16, 2010. PMID: 21162656, by Guastini L, Mora R, Dellepiane M, Santomauro V, Giorgio M, Salami A. ENT Department, University of Genoa, Genoa, Italy. [Email: renzomora@libero.it]

1 Star2 Stars3 Stars4 Stars5 Stars (10 votes, average: 3.30 out of 5)
Loading...



Leave a Reply